Seminars in Oncology
Volume 32, Issue 3 , Pages 336-350 , June 2005

New Agents in the Management of Advanced Mesothelioma

  • Nicholas J. Vogelzang

      Affiliations

    • Nevada Cancer Institute, Las Vegas, NV
    • Corresponding Author InformationAddress reprint requests to Nicholas J. Vogelzang, MD, Nevada Cancer Institute 10000 W Charleston Blvd, Las Vegas, NV 89135
    • ,
  • Camillo Porta

      Affiliations

    • Medical Oncology, IRCCS San Matteo University Hospital, Pavia, Italy
    • Salvatore Maugeri Foundation, Pavia, Italy; Italian Mesothelioma Group (GIMe)
    • ,
  • Luciano Mutti

      Affiliations

    • Local Health Authority 11-Piedmont, Vercelli, Italy
    • Salvatore Maugeri Foundation, Pavia, Italy; Italian Mesothelioma Group (GIMe)

References 

  1. http://apps.nccd.cdc.gov/USCS/TableV.asp?group=da&Year=2000
  2. Alberts A , Falkson G , Goedhals L , et al.   Malignant pleural mesothelioma (A disease unaffected by current therapeutic maneuvers) . J Clin Oncol . 1988;6:527–535
  3. Tomek S , Manegold C . Chemotherapy for malignant pleural mesothelioma (Past results and recent developments) . Lung Cancer . 2004;45(suppl 1):S103–S119
  4. Rusch V  From the International Mesothelioma Interest Group . A proposed new international TNM staging system for malignant pleural mesothelioma . Chest . 1995;108:1122–1128
  5. Sugarbaker D , Strauss GM , Lynch TJ , et al.   Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma . J Clin Oncol . 1993;11:1172–1178
  6. Curran D , Sahmoud T , Therasse P , et al.   Prognostic factors in patients with pleural mesothelioma (The European Organization for Research and Treatment of Cancer experience) . J Clin Oncol . 1998;16:145–152
  7. Herndon J , Green MR , Chahinian AP , et al.   Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B . Chest . 1998;113:723–731
  8. Mikulski S , Costanzi JJ , Vogelzang NJ , et al.   Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma . J Clin Oncol . 2002;20:274–281
  9. Edwards J , Abrams KR , Leverment JN , et al.   Prognostic factors for malignant mesothelioma in 142 patients (Validation of CALGB and EORTC prognostic scoring systems) . Thorax . 2000;55:731–735
  10. Vogelzang N , Taub R , Shin D , et al.   Phase III randomized trial of Onconase (ONC) vs. doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM) (Analysis of survival) . Proc Am Soc Clin Oncol . 2000;19:577a; (abstr 2274)
  11. Vogelzang N , Rusthoven JJ , Symanowski J , et al.   Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma . J Clin Oncol . 2003;21:2636–2644
  12. Symanowski J , Rusthoven J , Nguyen B , et al.   Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma . Proc Am Soc Clin Oncol . 2003;22:647; (abstr 2602)
  13. Gordon G , Jensen RV , Hsiao LL , et al.   Using gene expression ratios to predict outcome among patients with mesothelioma . J Natl Cancer Inst . 2003;95:598–605
  14. Gordon G , Jensen RV , Hsiao LL , et al.   Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma . Cancer Res . 2002;62:4963–4967
  15. Singhal S , Wiewrodt R , Malden LD , et al.   Gene expression profiling of malignant mesothelioma . Clin Cancer Res . 2003;9:3080–3097
  16. Hopper K , Singapuri K , Finkel A . Body CT and oncologic imaging . Radiology . 2000;215:27–40
  17. Thiesse P , Ollivier L , Di Stefano-Louineau D , et al.  Groupe Francais d’Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer   Response rate accuracy in oncology trials (Reasons for interobserver variability) . J Clin Oncol . 1995;15:3507–3514
  18. Therasse P , Arbuck SG , Eisenhauer EA , et al.  European Organization for Research and Treatment of Cancer  National Cancer Institute of the United States  National Cancer Institute of Canada   New guidelines to evaluate the response to treatment in solid tumors . J Natl Cancer Inst . 2000;92:205–216
  19. van Klaveren R , Aerts JG , de Bruin H , et al.   Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma . Lung Cancer . 2004;43:63–69
  20. Monetti F , Casanova S , Grasso A , et al.   Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma (Report of four cases) . Lung Cancer . 2004;43:71–74
  21. Armato S , Oxnard GR , MacMahon H , et al.   Measurement of mesothelioma on thoracic CT scans (A comparison of manual and computer-assisted techniques) . Med Phys . 2004;31:1105–1115
  22. Byrne M , Nowak AK . Modified RECIST criteria for assessment of response in malignant pleural mesothelioma . Ann Oncol . 2004;15:257–260
  23. Entwisle J . The use of magnetic resonance imaging in malignant mesothelioma . Lung Cancer . 2004;45(suppl 1):S69–S71
  24. Wang Z , Reddy GP , Gotway MB , et al.   Malignant pleural mesothelioma (Evaluation with CT, MR imaging, and PET) . Radiographics . 2004;24:105–119
  25. Eibel R , Tuengerthal S , Schoenberg SO . The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma . Curr Opin Oncol . 2003;15:131–138
  26. Stewart D , Waller D , Edwards J , et al.   Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma? . Eur J Cardiothorac Surg . 2003;24:1019–1024
  27. Medved M , et al.   Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients (Variability and changes in tumor tissue over time) . J Magn Reson Imaging . 2004;20:122–128
  28. Beziat C , Pilleul F , Yzebe D , et al.   Detection of liver metastases in colorectal cancer on chemotherapy. Comparative study between MRI with teslascan and computed tomography with intravenous contrast media . J Radiol . 2004;85:307–311
  29. Golder W . Magnetic resonance spectroscopy in clinical oncology . Onkologie . 2004;27:304–309
  30. Nanni C , Castellucci P , Farsad M , et al.   Role of 18F-FDG PET for evaluating malignant pleural mesothelioma . Cancer Biother Radiopharm . 2004;19:149–154
  31. Zubeldia J , Abou-Zied M , Nabi H . Evaluation of patients with known mesothelioma with 18F-fluorodeoxyglucose and PET. Comparison with computed tomography . Clin Positron Imaging . 2000;3:165–170
  32. Ng D , Hain SF , O’Doherty MJ , et al.   Prognostic value of FDG PET imaging in malignant pleural mesothelioma . J Nucl Med . 2000;41:1443–1444
  33. Benard F , Sterman D , Smith RJ , et al.   Prognostic value of FDG PET imaging in malignant pleural mesothelioma . J Nucl Med . 1999;4:1241–1245
  34. Benard F , Sterman D , Smith RJ , et al.   Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography . Chest . 1998;114:713–722
  35. Sharma A , Fidias P , Hayman LA , et al.   Patterns of lymphadenopathy in thoracic malignancies . Radiographics . 2004;24:419–434
  36. Flores R , Akhurst T , Gonen M , et al.   Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma . J Thorac Cardiovasc Surg . 2003;126:11–16
  37. Flores R . Role of PET in malignant pleural mesothelioma. Abstracts of the VII Meeting of the International Mesothelioma Interest Group (IMIG) . 2004;54
  38. Vogelzang N , Herndon JE , Miller A , et al.   High-dose paclitaxel plus G-CSF for malignant mesothelioma (CALGB phase II study 9234) . Ann Oncol . 1999;10:597–600
  39. Kindler H , Millard F , Herndon JE , et al.   Gemcitabine for malignant mesothelioma (A phase II trial by the Cancer and Leukemia Group B) . Lung Cancer . 2001;31:311–317
  40. Kindler H , Herndon J , Vogelzang N , et al.   CPT-11 in malignant mesothelioma (A phase II trial by the Cancer and Leukemia Group B (CALGB 9733)) . Proc Am Soc Clin Oncol . 2000;19: (abstr 1978)
  41. Middleton G , Smith IE , O’Brien ME , et al.   Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma . Ann Oncol . 1998;9:269–273
  42. Byrne M , Davidson JA , Musk AW , et al.   Cisplatin and gemcitabine treatment for malignant mesothelioma (A phase II study) . J Clin Oncol . 1999;17:25–30
  43. Nowak A , Byrne MJ , Williamson R , et al.   A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma . Br J Cancer . 2002;87:491–496
  44. Steele J , Shamash J , Evans MT , et al.   Phase II study of vinorelbine in patients with malignant pleural mesothelioma . J Clin Oncol . 2000;18:3912–3917
  45. Gralla R , Hollen PJ , Liepa AM , et al.   Improving quality of life in patients with malignant pleural mesothelioma (Results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso instrument) . Proc Am Soc Clin Oncol . 2003;22:621; (abstr 2496)
  46. Paoletti P , Pistolesi M , Rusthoven JJ , et al.   Correlation of pulmonary function tests with best tumor response status (Results from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma) . Proc Am Soc Clin Oncol . 2003;22:659; (abstr 2651)
  47. Girling D , Muers MF , Qian W , et al.   Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council . Semin Oncol . 2002;29:97–101
  48. Linden C , Mercke C , Albrechtsson U , et al.   Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas (A nonrandomized phase II study) . Eur Respir J . 1996;9:2565–2572
  49. Tomek S , Emri S , Krejcy K , et al.   Chemotherapy for malignant pleural mesothelioma (Past results and recent developments) . Br J Cancer . 2003;88:167–174
  50. van Haarst J , Baas P , Manegold C , et al.   Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma . Br J Cancer . 2002;86:342–345
  51. Favaretto A , Aversa SM , Paccagnella A , et al.   Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma (A multicentric phase II study) . Cancer . 2003;97:2791–2797
  52. Maisano R , Caristi N , Toscano G , et al.   Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma (Results of a pilot study) . Tumori . 2001;87:391–393
  53. Fizazi K , Doubre H , Le Chevalier T , et al.   Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma (Results of a phase II study) . J Clin Oncol . 2003;21:349–354
  54. Porta C , Zimatore M , Biscaldi E , et al.   Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment of malignant mesothelioma patients. Abstracts of the VII Meeting of the International Mesothelioma Interest Group (IMIG) . 2004;83
  55. Belani C . Chemotherapy regimens in advanced non small-cell lung cancer (Recent randomized trials) . Clin Lung Cancer . 2000;2(suppl 1):S7–S10
  56. Baas P . First line chemotherapy for MM: are all doublets equal? Abstracts of the VII Meeting of the International Mesothelioma Interest Group (IMIG) . 2004;62–63
  57. Breau J , Boaziz C , Morere JJF . Combination therapy with cisplatin, Adriamycin, bleomycin and mytomycin C plus sytemic and intrapleural hyaluronidase in 25 consecutive cases of stages II, III pleural mesothelioma . 1991; Abstracts of the 1st International Mesothelioma Conference, Paris, France
  58. Pennucci M , Ardizzoni A , Pronzato P , et al.  Italian Lung Cancer Task Force   Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma (A phase II FONICAP trial) . Cancer . 1997;79:1897–1902
  59. Pinto C , Marino A , Guaraldi M , et al.   Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma (A phase II study) . Am J Clin Oncol . 2001;24:143–147
  60. Shih C , Chen VJ , Gossett LS , et al.   LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes . Cancer Res . 1997;57:1116–1123
  61. Taylor E , Kuhnt D , Shih C , et al.   A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase . J Med Chem . 1992;35:4450–4454
  62. Chen V , Bewley JR , Smith PG , et al.   An assessment of the antithymine and antipurine characteristics of MTA (LY231514) in CCRF-CEM cells . Adv Enzyme Regul . 2000;40:143–154
  63. Wang Y , Zhao R , Chattopadhyay S , et al.   A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed . Cancer Res . 2002;62:6434–6437
  64. Chen V , Bewley JR , Andis SL , et al.   Preclinical cellular pharmacology of LY231514 (MTA) (a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells) . Br J Cancer . 1998;78(suppl 3):27–34
  65. Rinaldi D . Overview of phase I trials of multitargeted antifolate (MTA, LY231514) . Semin Oncol . 1999;26(suppl 6):82–88
  66. Adjei A . Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent . Clin Cancer Res . 2004;10:4276s–4280s
  67. Scagliotti G , Shin DM , Kindler HL , et al.   Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma . J Clin Oncol . 2003;21:1556–1561
  68. Rusthoven J , Eisenhauer E , Butts C , et al.  National Cancer Institute of Canada Clinical Trials Group   Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer (A phase II study) . J Clin Oncol . 1999;17:1194
  69. Martin M , Spielmann M , Namer M , et al.   Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines . Ann Oncol . 2003;14:1246–1252
  70. Hochster H . The role of pemetrexed in the treatment of colorectal cancer . Semin Oncol . 2002;29(suppl 18):54–56
  71. Diaz-Rubio E . New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers . Oncologist . 2004;9:282–294
  72. Paz-Ares L , Ciruelos E , Garcia-Carbonero R , et al.   Pemetrexed in bladder, head and neck, and cervical cancers . Semin Oncol . 2002;29(suppl 18):69–75
  73. Thodtmann R , Depenbrock H , Dumez H , et al.   Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin . J Clin Oncol . 1999;17:3009–3016
  74. Morgan S , Baggott JE , Vaughn WH , et al.   The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis . Arthritis Rheum . 1990;33:9–18
  75. Smith G , Amyx H , Boytos CM , et al.   Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid . Cancer Res . 1995;55:6117–6125
  76. Alati T , Worzalla JF , Shih C , et al.   Augmentation of the therapeutic activity of lometrexol—(6-R)5,10-dideazatetrahydrofolate—by oral folic acid . Cancer Res . 1996;56:2331–2335
  77. Bunn P , Paoletti P , Niyikiza C , et al.   Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite . Proc Am Soc Clin Oncol . 2001;20: (abstr 300)
  78. Niyikiza C , Baker SD , Seitz DE , et al.   Homocysteine and methylmalonic acid (markers to predict and avoid toxicity from pemetrexed therapy) . Mol Cancer Ther . 2002;1:545–552
  79. Vogelzang NJ , Boyer MJ , et al.   Effect of folic acid and vitamin B12 supplementation on risk-benefit ratio from phase III study of pemetrexed + cisplatin versus cisplatin in malignant pleural mesothelioma . Proc Am Soc Clin Oncol . 2003;22:657; (abstr 2644)
  80. Rusch V . Pemetrexed and cisplatin for malignant pleural mesothelioma (A new standard of care?) . J Clin Oncol . 2003;21:2629–2630
  81. Leland P , Raines RT . Cancer chemotherapy—Ribonucleases to the rescue . Chem Biol . 2001;8:405–413
  82. Vogelzang N , Shin D , Costanzi J , et al.   Phase III randomized trial of Onconase (ONC) vs. doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM) (Analysis of survival) . Proc Am Soc Clin Oncol . 2000;19:577a; (abstr 2274)
  83. Roskoski R . The ErbB/HER receptor protein-tyrosine kinases and cancer . Biochem Biophys Res Commun . 2004;319:1–11
  84. Herbst R . Review of epidermal growth factor receptor biology . Int J Radiat Oncol Biol Phys . 2004;59(suppl):21–26
  85. Mendelsohn J , Baselga J . Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer . J Clin Oncol . 2003;21:2787–2799
  86. Blume-Jensen P , Hunter T . Oncogenic kinase signalling . Nature . 2001;411:355–365
  87. Mellstedt H . Monoclonal antibodies in human cancer . Drugs Today (Barc) . 2003;39(suppl C):1–16
  88. Cersosimo R . Monoclonal antibodies in the treatment of cancer, Part 1 . Am J Health Syst Pharm . 2003;60:1531–1548
  89. Laskin J , Sandler AB . Epidermal growth factor receptor (A promising target in solid tumours) . Cancer Treat Rev . 2004;30:1–17
  90. Ciardiello F . Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents . Drugs . 2000;60(suppl 1):25–32
  91. Blackledge G , Averbuch S . Gefitinib (’Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors . Br J Cancer . 2004;90:566–572
  92. Shepherd F , Pereira J , Ciuleanu TE , et al.   A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial . J Clin Oncol . 2004;22(suppl):622s; (abstr 7022)
  93. Govindan R , Ritter J , Suppiah R . EGFR and HER-2 overexpression in malignant mesothelioma . Proc Am Soc Clin Oncol . 2001;20: (abstr 3106)
  94. Janne P , Taffaro ML , Salgia R , et al.   Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma . Cancer Res . 2002;62:5242–5247
  95. Govindan R , Kratzke RA , Herndon JE , et al.   Gefitinib in patients with malignant mesothelioma (MM) (A phase II study by the Cancer and Leukemia Group B (CALGB 30101)) . Proc Am Soc Clin Oncol . 2003;22:630; (abstr 2535)
  96. Garland L , Rankin C , Scott K , et al.   Molecular correlates of the EGFR signaling pathway in association with SWOG S0218 (A phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM)) . J Clin Oncol . 2004;22(suppl): (abstr)
  97. Yarden Y , Escobedo JA , Kuang WJ , et al.   Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors . Nature . 1986;323:226–232
  98. Ostman A , Heldin CH . Involvement of platelet-derived growth factor in disease (Development of specific antagonists) . Adv Cancer Res . 2001;80:1–38
  99. Langerak A , van der Linden-van Beurden CA , Versnel MA . Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines . Biochim Biophys Acta . 1996;1305:63–70
  100. Xu X , Shen J , Mall JW , et al.   In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide (Mechanisms of action) . Biochem Pharmacol . 1999;58:1405–1413
  101. Blaskovich M , Lin Q , Delarue FL , et al.   Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice . Nat Biotechnol . 2000;18:1065–1070
  102. Madhusudan S , Ganesan TS . Tyrosine kinase inhibitors in cancer therapy . Clin Biochem . 2004;37:618–635
  103. Cacciotti P , Barvone D , Porta C , et al.   STI 571 and Gemcitabine combined cell treatment as a novel approach to malignant mesothelioma treatment. Abstracts of the VII Meeting of the International Mesothelioma Interest Group (IMIG) . 2004;99
  104. Villano J , Husain AN , Stadler WM , et al.   A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM) . J Clin Oncol . 2004;22(suppl): (abstr 7200)
  105. Porta C: Personal communication.
  106. George D , Michaelson D , Oh WK , et al.   Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma . Proc Am Soc Clin Oncol . 2003;22:385; (abstr 1548)
  107. Herbst R . Targeted therapy in non-small-cell lung cancer . Oncology (Huntingt) . 2002;16(suppl 9):19–24
  108. Herbst R , Hidalgo M , Pierson AS , et al.   Angiogenesis inhibitors in clinical development for lung cancer . Semin Oncol . 2002;29(suppl 4):66–77
  109. Ferrara N , Hillan KJ , Gerber HP , et al.   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer . Nat Rev Drug Discov . 2004;3:391–400
  110. Underiner T , Ruggeri B , Gingrich DE . Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy . Curr Med Chem . 2004;11:731–745
  111. Glade-Bender J , Kandel JJ , Yamashiro DJ . VEGF blocking therapy in the treatment of cancer . Expert Opin Biol Ther . 2003;3:263–276
  112. Konig J , Tolnay E , Wiethege T , et al.   Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma . Virchows Arch . 1999;435:8–12
  113. Kumar-Singh S , Weyler J , Martin MJ , et al.   Angiogenic cytokines in mesothelioma (A study of VEGF, FGF-1 and -2, and TGF beta expression) . J Pathol . 1999;189:72–78
  114. Ohta Y , Shridhar V , Bright RK , et al.   VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours . Br J Cancer . 1999;81:54–61
  115. Zebrowski B , Yano S , Liu W , et al.   Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions . Clin Cancer Res . 1999;5:3364–3368
  116. Strizzi L , Catalano A , Vianale G , et al.   Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma . J Pathol . 2001;193:468–475
  117. Cacciotti P , Strizzi L , Vianale G , et al.   The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor . Am J Respir Cell Mol Biol . 2002;26:189–193
  118. Ohta Y , Kimura K , Tamura M , et al.   Biological characteristics of carcinomatosa pleuritis in orthotopic model systems using immune-deficient rats . Int J Oncol . 2001;18:499–505
  119. Casella I , Feccia T , Chelucci C , et al.   Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor . Blood . 2003;101:1316–1323
  120. Fong T , Shawver LK , Sun L , et al.   SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types . Cancer Res . 1999;59:99–106
  121. Kindler HL , Chien K , Stadler WM , et al.   SU5416 in Malignant Mesothelioma (A University of Chicago Phase II Consortium Study) . Proc Am Soc Clin Oncol . 2001;20: (abstr 1359)
  122. Aklilu M , Kindler HL , Gajewski TF , et al.   Toxicities of the antiangiogenic agent SU5416 in phase II studies . Proc Am Soc Clin Oncol . 2002;21: (abstr 1921)
  123. Leucovorin and fluorouracil with or without SU5416 in treating patients with metastatic colorectal cancer. http://www.ClinicalTrials.gov
  124. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  125. Kerbel R , Viloria-Petit A , Klement G , et al.   ’Accidental’ anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples . Eur J Cancer . 2000;36:1248–1257
  126. Kumar S , Witzig TE , Rajkumar SV . Thalidomid (Current role in the treatment of non-plasma cell malignancies) . J Clin Oncol . 2004;22:2477–2488
  127. Dimopoulos M , Anagnostopoulos A , Weber D . Treatment of plasma cell dyscrasias with thalidomide and its derivatives . J Clin Oncol . 2003;21:4444–4454
  128. Amato R . Thalidomide therapy for renal cell carcinoma . Crit Rev Oncol Hematol . 2003;46(suppl):S59–S65
  129. Pavlakis N , Williams G , Harvey R , et al.   Thalidomide alone and in combination with cisplatin/gemcitabine chemotherapy for malignant mesothelioma (MM) (Preliminary results from two phase II studies) . Proc Am Soc Clin Oncol . 2002;22: (abstr 1885)
  130. Bottaro D , Rubin JS , Faletto DL , et al.   Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product . Science . 1991;251:802–804
  131. Zhang Y , Vande Woude GF . HGF/SF-met signaling in the control of branching morphogenesis and invasion . J Cell Biochem . 2003;88:408–417
  132. Stuart K , Riordan SM , Lidder S , et al.   Hepatocyte growth factor/scatter factor-induced intracellular signalling . Int J Exp Pathol . 2000;81:17–30
  133. Funakoshi H , Nakamura T . Hepatocyte growth factor (From diagnosis to clinical applications) . Clin Chim Acta . 2003;327:1–23
  134. Harvey P , Warn A , Newman P , et al.   Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas . J Pathol . 1996;180:389–394
  135. Klominek J , Baskin B , Liu Z , et al.   Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor . Int J Cancer . 1998;76:240–249
  136. Harvey P , Warn A , Dobbin S , et al.   Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology . Br J Cancer . 1998;77:1052–1059
  137. Thirkettle I , Harvey P , Hasleton PS , et al.   Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas . Histopathology . 2000;36:522–528
  138. Tolnay E , Kuhnen C , Wiethege T , et al.   Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma . J Cancer Res Clin Oncol . 1998;124:291–296
  139. Harvey P , Clark IM , Jaurand MC , et al.   Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases . Br J Cancer . 2000;83:1147–1153
  140. Cacciotti P , Libener R , Betta P , et al.   SV40 replication in human mesothelial cells induces HGF/Met receptor activation (A model for viral-related carcinogenesis of human malignant mesothelioma) . Proc Natl Acad Sci U S A . 2001;98:12032–12037
  141. Sattler M , Pride YB , Ma P , et al.   A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase . Cancer Res . 2003;63:5462–5469
  142. Vande Woude G: Personal ccmmunication
  143. Harding M . Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy . Clin Cancer Res . 2003;9:2882–2886
  144. Raymond E , Alexandre J , Faivre S , et al.   Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer . J Clin Oncol . 2004;22:2336–2347
  145. Schuler W , Sedrani R , Cottens S , et al.   SDZ RAD, a new rapamycin derivative (Pharmacological properties in vitro and in vivo) . Transplantation 1997 . 1997;64:36–42
  146. Panwalkar A , Verstovsek S , Giles FJ . Mammalian target of rapamycin inhibition as therapy for hematologic malignancies . Cancer . 2004;100:657–666
  147. Atkins M , Hidalgo M , Stadler WM , et al.   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma . J Clin Oncol . 2004;22:909–918
  148. Adams J . Development of the proteasome inhibitor PS-341 . Oncologist . 2002;7:9–16
  149. Baldwin A . Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB . J Clin Invest . 2001;107:241–246
  150. Roff M , Thompson J , Rodriguez MS , et al.   Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo . J Biol Chem . 1996;271:7844–7850
  151. Krappmann D , Emmerich F , Kordes U , et al.   Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells . Oncogene . 1999;18:943–953
  152. Kordes U , Krappmann D , Heissmeyer V , et al.   Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells . Leukemia . 2000;14:399–402
  153. Janssen Y , Driscoll KE , Howard B , et al.   Asbestos causes translocation of p65 protein and increases NF-kappa B DNA binding activity in rat lung epithelial and pleural mesothelial cells . Am J Pathol . 1997;151:389–401
  154. An B , Goldfarb RH , Siman R , et al.   Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts . Cell Death Differ . 1998;5:1062–1075
  155. Sartore-Bianchi A , Nici L , Porta C , et al.   The combination of the novel camptothecin analogue Gimatecan (ST1481) plus the proteasome inhibitor PS341 produces an enhanced pro-apoptotic effect in a malignant mesothelioma cell line . Proc Am Assoc Cancer Res . 2003;44: (abstr R729)
  156. Adams J , Kauffman M . Development of the proteasome inhibitor velcade (Bortezomib) . Cancer Invest . 2004;22:304–311
  157. Davis N , Taber DA , Ansari RH , et al.   Phase II trial of PS-341 in patients with renal cell cancer (A University of Chicago phase II consortium study) . J Clin Oncol . 2004;22:115–119
  158. Nowak A , Lake RA , Kindler HL , et al.   New approaches for mesothelioma (Biologics, vaccines, gene therapy, and other novel agents) . Semin Oncol . 2002;29:82–96

PII: S0093-7754(05)00080-1

doi: 10.1053/j.seminoncol.2005.02.010

Seminars in Oncology
Volume 32, Issue 3 , Pages 336-350 , June 2005

Article Tools

* Image Usage & Resolution